Biomea Fusion

Biomea Fusion EPS

The Earnings per Share (EPS) of Biomea Fusion (BMEA) as of Nov 18, 2026 is -0.85 USD. In the previous year, Earnings per Share (EPS) was -3.82 USD — a change of -77.61% (higher).

EPS

-0.85USD

YoY

-77.61%

Last updated:

Earnings per Share (EPS) of Biomea Fusion is 2025 -0.85 USD. Earnings per Share (EPS) of Biomea Fusion was 2024 -3.82 USD. It decreases by -77.61% higher compared to the previous year.

The Biomea Fusion EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2024
-3.82 USD
Jan 1, 2025
-0.85 USD
Jan 1, 2026 (e)
-0.74 USD
Jan 1, 2027 (e)
-0.77 USD
Jan 1, 2028 (e)
-0.79 USD
Jan 1, 2029 (e)
-0.80 USD
Jan 1, 2030 (e)
-0.72 USD
Jan 1, 2031 (e)
1.43 USD
The Biomea Fusion EPS history
YEAREPSYoY
est1.43USD-298.33%
est-0.72USD-10.00%
est-0.80USD+1.84%
est-0.79USD+2.36%
est-0.77USD+4.28%
est-0.74USD-13.90%
-0.85USD-77.61%
-3.82USD+16.39%
-3.28USD+20.66%
-2.72USD+91.63%
-1.42USD+626.42%
-0.20USD-2.21%
-0.20USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomea Fusion Stock analysis

What does Biomea Fusion do? Biomea Fusion, Inc. generates revenue through the development and commercialization of covalent small molecule drugs targeting genetically defined cancers and metabolic disorders. The company's lead product candidate, BMF-219, is an orally bioavailable covalent inhibitor of menin designed for treating leukemias with MLL fusion protein and other menin-dependent tumors. The firm utilizes its FUSION System discovery platform to advance a pipeline of covalent small molecule product candidates. Biomea Fusion focuses on hematological oncology and metabolic disease markets, targeting patients with specific genetic markers for treatment with its proprietary drug candidates. The company's primary revenue stream comes from the development and eventual commercialization of its drug candidates, particularly BMF-219, which is in clinical development for hematological malignancies. Biomea Fusion's pipeline includes multiple preclinical covalent programs targeting select cancer types, with the FUSION System platform enabling the discovery of novel covalent small molecules. The firm's target segments include patients with genetically defined cancers, particularly those with MLL fusion protein in leukemias, and metabolic disorders requiring targeted therapy. Biomea Fusion's business model centers on developing irreversible small molecules for specific genetic targets, with BMF-219 representing the most advanced candidate in its pipeline. The company's revenue potential is tied to the successful progression of BMF-219 through clinical trials and subsequent market approval. The firm's focus on covalent small molecule drugs for genetically defined conditions positions it within the biopharmaceutical sector, targeting patients with specific molecular profiles for treatment. Biomea Fusion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomea Fusion stock

Earnings per Share (EPS) of Biomea Fusion is -0.85 USD in 2025.

Earnings per Share (EPS) of Biomea Fusion changed from -3.82 USD to -0.85 USD, representing a -77.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Biomea Fusion since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biomea Fusion

All Key Metrics — Biomea Fusion